Testing Data
(Surface Staining of buffy coat differentiated monocytes by Mouse anti Human CD169:RPE )
Mouse anti-Human CD169 Monoclonal Antibody | anti-CD169 antibody
Mouse Anti Human CD169: RPE
Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant.
Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant.
Use 10ul of the undiluted reagent to label 1x106 cells in 100ul
This product should be stored undiluted.
This product is photosensitive and should be protected from light.
Testing Data
(Surface Staining of buffy coat differentiated monocytes by Mouse anti Human CD169:RPE )
Testing Data
(Surface Staining of buffy coat differentiated monocytes by Mouse anti Human CD169:RPE )
Testing Data
(Mouse anti Human CD169 antibody, clone 7-239 used for the evaluation of CD169 expression by monocyte-derived macrophages following exposure to ? interferon using flow cytometry and western blottingImage caption:Siglec-1 expression by MDMs is enhanced via IFN exposure and leads to VLP internalization.(A) Representative Siglec-1 and tetherin surface expression of GM-CSF matured MDMs together with 24 h IFN alpha stimulation (1000 U/ml). (B) Western blot of Siglec-1 and actin upon incubation with increasing amounts of IFN alpha in GM-CSF derived MDMs. (C) Enhanced capture of HIV-1 Gag-EGFP VLPs by MDMs stimulated with 1000 U/ml IFN alpha as measured by p24 ELISA. (D) MDMs were incubated with 400 ng of sucrose-purified HIV-1 Gag-EGFP VLPs either treated with 1.0 U/ul neuraminidase, untreated or from 293T cultured in the presence of 10 ?M PDMP. Cell-associated HIV-1 p24 was quantified by ELISA.From: Hammonds JE, Beeman N, Ding L, Takushi S, Francis AC, Wang J-J, et al. (2017)Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1.PLoS Pathog 13(1): e1006181.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human CD169 antibody, clone 7-239 used for the evaluation of CD169 expression by monocyte-derived macrophages following exposure to ? interferon using flow cytometry and western blottingImage caption:Siglec-1 expression by MDMs is enhanced via IFN exposure and leads to VLP internalization.(A) Representative Siglec-1 and tetherin surface expression of GM-CSF matured MDMs together with 24 h IFN alpha stimulation (1000 U/ml). (B) Western blot of Siglec-1 and actin upon incubation with increasing amounts of IFN alpha in GM-CSF derived MDMs. (C) Enhanced capture of HIV-1 Gag-EGFP VLPs by MDMs stimulated with 1000 U/ml IFN alpha as measured by p24 ELISA. (D) MDMs were incubated with 400 ng of sucrose-purified HIV-1 Gag-EGFP VLPs either treated with 1.0 U/ul neuraminidase, untreated or from 293T cultured in the presence of 10 ?M PDMP. Cell-associated HIV-1 p24 was quantified by ELISA.From: Hammonds JE, Beeman N, Ding L, Takushi S, Francis AC, Wang J-J, et al. (2017)Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1.PLoS Pathog 13(1): e1006181.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human CD169 antibody, clone 7-239 used for the evaluation of CD169 expression by monocyte-derived macrophages following exposure to ? interferon immunofluorescence.Image caption:Siglec-1 expression by MDMs is enhanced via IFN exposure and leads to VLP internalization.(E) Sucrose purified, HIV-1 Gag-EGFP VLPs treated with neuraminidase (NA) or untreated (F) were added to mature GM-CSF derived MDM cultures on day 8 for 6 hours. Cells were then washed, fixed, immunostained for Siglec-1 (red) and DAPI co-stained. Size bar = 21?m for (E) and 15?m for (F).From: Hammonds JE, Beeman N, Ding L, Takushi S, Francis AC, Wang J-J, et al. (2017)Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1.PLoS Pathog 13(1): e1006181.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human CD169 antibody, clone 7-239 used for the evaluation of CD169 expression by monocyte-derived macrophages following exposure to ? interferon immunofluorescence.Image caption:Siglec-1 expression by MDMs is enhanced via IFN exposure and leads to VLP internalization.(E) Sucrose purified, HIV-1 Gag-EGFP VLPs treated with neuraminidase (NA) or untreated (F) were added to mature GM-CSF derived MDM cultures on day 8 for 6 hours. Cells were then washed, fixed, immunostained for Siglec-1 (red) and DAPI co-stained. Size bar = 21?m for (E) and 15?m for (F).From: Hammonds JE, Beeman N, Ding L, Takushi S, Francis AC, Wang J-J, et al. (2017)Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1.PLoS Pathog 13(1): e1006181.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human CD169 antibody, clone 7-239 used for the evaluation of CD169 expression by monocyte-derived macrophages by immunofluorescence.Image caption:Time course of HIV-1 Gag-EGFP internalization within MDMs and colocalization with Siglec-1.(A-D) 400 ng of sucrose-purified HIV-1 Gag-EGFP VLPs were added to MDM cultures and allowed to attach and be internalized from 10’ to 6 hours. At the indicated times, MDMs were washed, fixed in 4% PFA and immunostained with Siglec-1 (red, mAb clone 7–239) and DAPI co-stained. Shown are cells representative of the populations examined at each timepoint. Size bars = 10?m.From: Hammonds JE, Beeman N, Ding L, Takushi S, Francis AC, Wang J-J, et al. (2017)Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1.PLoS Pathog 13(1): e1006181.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human CD169 antibody, clone 7-239 used for the evaluation of CD169 expression by monocyte-derived macrophages by immunofluorescence.Image caption:Time course of HIV-1 Gag-EGFP internalization within MDMs and colocalization with Siglec-1.(A-D) 400 ng of sucrose-purified HIV-1 Gag-EGFP VLPs were added to MDM cultures and allowed to attach and be internalized from 10’ to 6 hours. At the indicated times, MDMs were washed, fixed in 4% PFA and immunostained with Siglec-1 (red, mAb clone 7–239) and DAPI co-stained. Shown are cells representative of the populations examined at each timepoint. Size bars = 10?m.From: Hammonds JE, Beeman N, Ding L, Takushi S, Francis AC, Wang J-J, et al. (2017)Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1.PLoS Pathog 13(1): e1006181.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human CD169 antibody, clone 7-239 used for the evaluation of CD169 expression by monocyte-derived macrophages by western blotting.Image caption:Siglec-1 RNAi interference and competitive inhibition by a GM3 glycan mimetic inhibits HIV-1 VLP internalization by MDMs.(A) MDMs were transfected with 60 nM control or Siglec-1 siRNA on day 8 after plating. Cell lysates were harvested and analyzed by Western blotting for Siglec-1 and actin expression. (B) MDMs were transfected with either control or Siglec-1 siRNA and 5 days later incubated with 400 ng of HIV-1 Gag-EGFP VLPs for 2 hr. Cells were washed and cell lysate p24 concentration determined by ELISA. (C) MDMs were pre-treated at RT with lactose or 3’-sialyllactose for 1 hour. Subsequently, MDMs were incubated with 400 ng of HIV-1 Gag-EGFP VLPs in the presence of compound for an additional hour. MDMs were then washed, cell lysates harvested and cell-associated p24 measured by ELISA. Error bars represent standard deviation; asterisks depict significant differences as measured by unpaired t-test.From: Hammonds JE, Beeman N, Ding L, Takushi S, Francis AC, Wang J-J, et al. (2017)Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1.PLoS Pathog 13(1): e1006181.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human CD169 antibody, clone 7-239 used for the evaluation of CD169 expression by monocyte-derived macrophages by western blotting.Image caption:Siglec-1 RNAi interference and competitive inhibition by a GM3 glycan mimetic inhibits HIV-1 VLP internalization by MDMs.(A) MDMs were transfected with 60 nM control or Siglec-1 siRNA on day 8 after plating. Cell lysates were harvested and analyzed by Western blotting for Siglec-1 and actin expression. (B) MDMs were transfected with either control or Siglec-1 siRNA and 5 days later incubated with 400 ng of HIV-1 Gag-EGFP VLPs for 2 hr. Cells were washed and cell lysate p24 concentration determined by ELISA. (C) MDMs were pre-treated at RT with lactose or 3’-sialyllactose for 1 hour. Subsequently, MDMs were incubated with 400 ng of HIV-1 Gag-EGFP VLPs in the presence of compound for an additional hour. MDMs were then washed, cell lysates harvested and cell-associated p24 measured by ELISA. Error bars represent standard deviation; asterisks depict significant differences as measured by unpaired t-test.From: Hammonds JE, Beeman N, Ding L, Takushi S, Francis AC, Wang J-J, et al. (2017)Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1.PLoS Pathog 13(1): e1006181.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(PE conjugated Mouse anti CD169 antibody, clone 7-239 used for the evaluation of CD169 expression on myeloid cell populations by flow cytometry. Mouse anti Human CD169 antibody, clone 7-239 used to block CD169 function on myeliod cells.Image caption:Siglec-1 mediates HIV-1 capture by IFN?-treated myeloid cells. A. Representative profiles of Siglec-1 staining in distinct myeloid cells cultured with or without 1000 U/ml of IFN? and assessed by FACS. Staining of matched-isotype control is also shown. The mean fold increase in fluorescence after IFN&apha; treatment of cells derived from three donors is shown in red numbers. B. Mean number of Siglec-1 antibody binding sites per cell displayed by different myeloid cells exposed to 1000 U/ml of IFN? for 48 h and assessed by quantitative FACS analysis. Data show mean values and SEM from four experiments including cells from 12 donors. C. Comparative binding of HIV-1NL4–3 to different myeloid cells ly exposed to 1000 U/ml of IFN? for 48 h. Cells were cultured with HIV-1NL4–3 for 4 h at 4°C, washed and lysed to measure p24Gag by ELISA. Data show mean values and SEM from two experiments including cells from six donors. D. Relative binding of HIV-1NL4–3 by different IFN?-treated myeloid cells that had been pre-incubated with 10 ug/ml of the indicated mAbs before HIV-1 exposure for 4 h at 4°C as described in C. To compare the effect of the mAbs in different myeloid cells, values were normalized to the level of HIV-1 binding by mock-treated cells (set to 100%). Data show mean values and SEM from two experiments including cells from six donors. Statistical differences were assessed with a paired t test in B and C, and with a one sample t-test in D.From: Pino M, Erkizia I, Benet S, Erikson E, Fernández-Figueras MT, Guerrero D, Dalmau J, Ouchi D, Rausell A, Ciuffi A, Keppler OT, Telenti A, Kräusslich HG, Martinez-Picado J, Izquierdo-Useros N.HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells.Retrovirology. 2015 May 7;12:37.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(PE conjugated Mouse anti CD169 antibody, clone 7-239 used for the evaluation of CD169 expression on myeloid cell populations by flow cytometry. Mouse anti Human CD169 antibody, clone 7-239 used to block CD169 function on myeliod cells.Image caption:Siglec-1 mediates HIV-1 capture by IFN?-treated myeloid cells. A. Representative profiles of Siglec-1 staining in distinct myeloid cells cultured with or without 1000 U/ml of IFN? and assessed by FACS. Staining of matched-isotype control is also shown. The mean fold increase in fluorescence after IFN&apha; treatment of cells derived from three donors is shown in red numbers. B. Mean number of Siglec-1 antibody binding sites per cell displayed by different myeloid cells exposed to 1000 U/ml of IFN? for 48 h and assessed by quantitative FACS analysis. Data show mean values and SEM from four experiments including cells from 12 donors. C. Comparative binding of HIV-1NL4–3 to different myeloid cells ly exposed to 1000 U/ml of IFN? for 48 h. Cells were cultured with HIV-1NL4–3 for 4 h at 4°C, washed and lysed to measure p24Gag by ELISA. Data show mean values and SEM from two experiments including cells from six donors. D. Relative binding of HIV-1NL4–3 by different IFN?-treated myeloid cells that had been pre-incubated with 10 ug/ml of the indicated mAbs before HIV-1 exposure for 4 h at 4°C as described in C. To compare the effect of the mAbs in different myeloid cells, values were normalized to the level of HIV-1 binding by mock-treated cells (set to 100%). Data show mean values and SEM from two experiments including cells from six donors. Statistical differences were assessed with a paired t test in B and C, and with a one sample t-test in D.From: Pino M, Erkizia I, Benet S, Erikson E, Fernández-Figueras MT, Guerrero D, Dalmau J, Ouchi D, Rausell A, Ciuffi A, Keppler OT, Telenti A, Kräusslich HG, Martinez-Picado J, Izquierdo-Useros N.HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells.Retrovirology. 2015 May 7;12:37.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(PE conjugatedMouse anti Human CD169 antibody, clone 7-239 used to block CD169 function on myeloid cells.Image caption:Siglec-1 mediates HIV-1 uptake into a storage compartment and enhances HIV-1 trans-infection specially in IFN?-treated monocytes and DCs. A. Uptake of HIV-1NL4–3 by different myeloid cells exposed to IFN?. Cells were cultured with HIV-1 to measure p24Gag by ELISA. Mean values and SEM from four experiments include cells from 12 donors. B. Fold change in HIV-1NL4–3 uptake of cells treated with bafilomycin A1 compared to untreated cells. Mean values and SEM include cells from three donors. C. Relative uptake of HIV-1NL4–3 by IFN?-treated myeloid cells pre-incubated with the indicated mAbs. Values are normalized to the level of HIV-1 uptake by mock-treated cells (set at 100%). Mean values and SEM from two experiments include cells from six donors. D. Confocal microscopy analysis of different IFN?-treated myeloid cells pulsed with HIV-1Cherry and stained for Siglec-1 (Alexa 488), HLA-DR (Alexa 647) and DAPI. (Top) Representative viral pattern for each kind of myeloid cell analyzed, showing maximum fluorescence intensity of four channels. (Bottom) Percentage of myeloid cells with distinct viral patterns: random distribution, polarized accumulation, and sac-like compartment formation, as illustrated in the left drawing. Mean values of 50 cells from two different donors are shown. E. HIV-1 transmission from IFN?-treated myeloid cells to a luciferase reporter CD4+ cell line. HIV-1 infection was determined by induced luciferase activity in relative light units (RLUs). Mean values and SEM from four experiments include cells from 12 donors. F. Relative HIV-1 transmission from IFN?-treated myeloid cells pre-incubated with the indicated mAbs. Values are normalized to the level of HIV-1 trans-infected by mock-treated cells. Mean values and SEM from two experiments include cells from six donors. Statistical differences were assessed with a paired t test in A and E, and with a one sample t-test in B, C and F.From: Pino M, Erkizia I, Benet S, Erikson E, Fernández-Figueras MT, Guerrero D, Dalmau J, Ouchi D, Rausell A, Ciuffi A, Keppler OT, Telenti A, Kräusslich HG, Martinez-Picado J, Izquierdo-Useros N.HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells.Retrovirology. 2015 May 7;12:37.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(PE conjugatedMouse anti Human CD169 antibody, clone 7-239 used to block CD169 function on myeloid cells.Image caption:Siglec-1 mediates HIV-1 uptake into a storage compartment and enhances HIV-1 trans-infection specially in IFN?-treated monocytes and DCs. A. Uptake of HIV-1NL4–3 by different myeloid cells exposed to IFN?. Cells were cultured with HIV-1 to measure p24Gag by ELISA. Mean values and SEM from four experiments include cells from 12 donors. B. Fold change in HIV-1NL4–3 uptake of cells treated with bafilomycin A1 compared to untreated cells. Mean values and SEM include cells from three donors. C. Relative uptake of HIV-1NL4–3 by IFN?-treated myeloid cells pre-incubated with the indicated mAbs. Values are normalized to the level of HIV-1 uptake by mock-treated cells (set at 100%). Mean values and SEM from two experiments include cells from six donors. D. Confocal microscopy analysis of different IFN?-treated myeloid cells pulsed with HIV-1Cherry and stained for Siglec-1 (Alexa 488), HLA-DR (Alexa 647) and DAPI. (Top) Representative viral pattern for each kind of myeloid cell analyzed, showing maximum fluorescence intensity of four channels. (Bottom) Percentage of myeloid cells with distinct viral patterns: random distribution, polarized accumulation, and sac-like compartment formation, as illustrated in the left drawing. Mean values of 50 cells from two different donors are shown. E. HIV-1 transmission from IFN?-treated myeloid cells to a luciferase reporter CD4+ cell line. HIV-1 infection was determined by induced luciferase activity in relative light units (RLUs). Mean values and SEM from four experiments include cells from 12 donors. F. Relative HIV-1 transmission from IFN?-treated myeloid cells pre-incubated with the indicated mAbs. Values are normalized to the level of HIV-1 trans-infected by mock-treated cells. Mean values and SEM from two experiments include cells from six donors. Statistical differences were assessed with a paired t test in A and E, and with a one sample t-test in B, C and F.From: Pino M, Erkizia I, Benet S, Erikson E, Fernández-Figueras MT, Guerrero D, Dalmau J, Ouchi D, Rausell A, Ciuffi A, Keppler OT, Telenti A, Kräusslich HG, Martinez-Picado J, Izquierdo-Useros N.HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells.Retrovirology. 2015 May 7;12:37.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
CD169 has an approximate molecular weight of 185 kDa and recognizes sialic acid-containing sugar chains. Structurally, it contains an extracellular domain containing 17 immunoglobulin-like domains and one v-set domain via which it binds its’ ligands. It also contains 16 C2-set domains which extend the binding site away from the surface of the cell. This extension helps bind granulocytes, B cells, erythrocytes and a subset of CD8 T cells (Eakin et al. 2016).
Increased expression of CD169 has been found to be associated with various conditions, including atherosclerosis, type I diabetes, chronic rejection and systemic sclerosis (Bornhöfft et al. 2018).
Mouse anti Human CD169 clone 7-239 has been used in flow cytometry experiments to measure cell surface expression of CD169 upon cell stimulation with IFN-alpha (OhAinle et al. 2018).
NCBI and Uniprot Product Information
NCBI Description
This gene encodes a member of the immunoglobulin superfamily. The encoded protein is a lectin-like adhesion molecule that binds glycoconjugate ligands on cell surfaces in a sialic acid-dependent manner. It is a type I transmembrane protein expressed only by a subpopulation of macrophages and is involved in mediating cell-cell interactions. Alternative splicing produces a transcript variant encoding an isoform that is soluble rather than membrane-bound; however, the full-length nature of this variant has not been determined. [provided by RefSeq, Jul 2008]
Uniprot Description
SIGLEC1: Acts as an endocytic receptor mediating clathrin dependent endocytosis. Macrophage-restricted adhesion molecule that mediates sialic-acid dependent binding to lymphocytes, including granulocytes, monocytes, natural killer cells, B-cells and CD8 T-cells. Preferentially binds to alpha-2,3-linked sialic acid. Binds to SPN/CD43 on T-cells. May play a role in hemopoiesis. Belongs to the immunoglobulin superfamily. SIGLEC (sialic acid binding Ig-like lectin) family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral
Chromosomal Location of Human Ortholog: 20p13
Cellular Component: plasma membrane; extracellular region; integral to membrane
Molecular Function: carbohydrate binding
Biological Process: cell-cell adhesion; cell-matrix adhesion; endocytosis; inflammatory response
Research Articles on CD169
Similar Products
Product Notes
The CD169 siglec1 (Catalog #AAA225768) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Mouse Anti Human CD169: RPE reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's CD169 can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS). FC/FACS: Max. Dilution: Neat Use 10ul of the undiluted reagent to label 1x106 cells in 100ul. Researchers should empirically determine the suitability of the CD169 siglec1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "CD169, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
